Patent intelligence · WO
WO 2015187736
FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI
FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI
Patent details — WO 2015187736
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Dec 10, 2015
- Expiration
- Dec 5, 2035
- Applicant
- ALLERGEN RES CORP [US]
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 70 A I, A61K 49/ 00 A I, A61K/94866
Quick answer
WO 2015187736 (FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI) is held by ALLERGEN RES CORP [US]. Status: granted. Granted Dec 10, 2015. Expires Dec 5, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGEN RES CORP [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 70 A I, A61K 49/ 00 A I, A61K/94866, A61P 43/ 00 A I, A61P/4300
More from ALLERGEN RES CORP [US]
Related pharmaceutical patents in our USPTO index.
-
CN 112638413
Oral immunotherapy unit dose dispensing systems and methods
granted -
US 2014356438
PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS
granted -
US 2014271721
PEANUT FORMULATIONS AND USES THEREOF
granted -
US 2014271836
MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION
granted -
US 2013209398
CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE
granted -
CA 2849366
COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER
granted -
US 2012003230
SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER
granted
Frequently asked questions
What is US patent 2015187736?
WO 2015187736 (FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI) is held by ALLERGEN RES CORP [US]. Status: granted. Granted Dec 10, 2015. Expires Dec 5, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2015187736?
ALLERGEN RES CORP [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does WO 2015187736 expire?
Our index shows an expiration date of Dec 5, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.